Antihypertensive Drug Combinations, Comparisons, and Therapeutic Intensity
Kenny Lin, MD, MPH
October 6, 2025
Although hypertension management is the bread and butter of family medicine, selecting antihypertensive medications is not always straightforward. A 2023 AFP article on initial management of hypertension in adults recommended, “Initial antihypertensive treatment should include an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), a long-acting dihydropyridine calcium channel blocker, or a thiazide diuretic.” But how should one choose among drug classes and single vs combination therapy?
Compared with monotherapy, combination antihypertensive drugs have the advantage of reaching blood pressure goals quicker, with similar tolerability. Expert consensus suggests that initial combination therapy is preferred “in patients with systolic blood pressure higher than 160 mm Hg or greater than 20 mm Hg above goal, or with diastolic blood pressure higher than 100 mm Hg or greater than 10 mm Hg above goal.” A 2024 study of US adults taking two classes of antihypertensives found that patients on fixed-dose combinations were 1.78 times more likely to have controlled blood pressure than patients on two separate pills. In June 2025, the US Food and Drug Administration first approved a triple antihypertensive drug, a combination of telmisartan, amlodipine, and indapamide.
Specific antihypertensive classes are indicated for special populations (eg, patients with heart failure, chronic kidney disease, diabetes). A randomized trial of more than 11,000 patients with hypertension at high risk of cardiovascular events found that despite similar blood pressure control, benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide (number needed to treat [NNT] = 45 to prevent a composite cardiovascular end point over 36 months). In the general hypertensive population, a Cochrane review found that over 5 years, thiazide diuretics have small advantages over calcium channel blockers (NNT = 100 to prevent a cardiovascular event; NNT = 84 to prevent heart failure) and ACE inhibitors (NNT = 167 to prevent one stroke).
Although lipid-lowering drugs and doses are classified by intensity, until recently no similar schema was available for antihypertensive drugs. A systematic review and meta-analysis of 484 placebo-controlled trials classified the average systolic blood pressure-lowering effects of 57 monotherapies and 189 combinations as low (< 10 mm Hg), moderate (10-19.9 mm Hg), and high (> 20 mm Hg) intensity. Unsurprisingly, most monotherapies had low efficacy, whereas dual or triple therapies generally produced moderate or high effects. Clinicians can use an online calculator derived from the review to estimate the efficacy of any antihypertensive drug and dose combination depending on the patient’s baseline blood pressure.